RePROM pilot/feasibility study in chronic kidney disease

Not Applicable

Completed

• Conditions: Advanced Chronic Kidney Disease; Urological and Genital Diseases

• Registration Number: ISRCTN12669006
• Lead Sponsor: niversity of Birmingham

Brief Summary

2018 Protocol article in https://pubmed.ncbi.nlm.nih.gov/30373785/ protocol (added 11/12/2020) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35304391/ (added 13/03/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-02-28
• Study Completion: 2020-12-31
• Last Update Posted: 27 March 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

1. Aged =18 years old
2. Ability to provide fully informed consent for participation in the study
3. Patients under the care of the renal services at Queen Elizabeth Hospital Birmingham (QEHB)
4. Patients meeting the trial definition of advanced CKD: an eGFR =6 and =15 mL/min/1.73m2 (inclusive) OR a projected risk of progression to end-stage renal failure within 2-years =20% using the 4-variable Tangri renal risk calculator

Exclusion Criteria

1. Patients unwilling to use the ePROM intervention
2. Patients who, in the opinion of the consenting professional, cannot speak, read or write English sufficiently well to complete the ePROM unaided
3. An episode of acute kidney injury (defined in accordance with national guidelines) within the last 3 months
4. Patients meeting the trial definition of End Stage Renal Disease (currently receiving dialysis/scheduled to start in the next 2 weeks OR received/scheduled date to receive a kidney transplant OR eGFR < = 5ml/min/1.73m2)
5. A terminal illness that, in the opinion of the consultant consultant assessing eligibility, is likely to lead to the death of the patient within 6 months of starting participation in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified